Immune treatment in COVID-19.
Rev Esp Quimioter
; 35 Suppl 1: 59-63, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2309886
ABSTRACT
Current immune treatment directed to avoid viral replication relies mainly in convalescent plasma and monoclonal antibodies (mAbs). No clinical benefit for convalescent plasma has been reported in a meta-analysis and systematic review compared to standard of care. MAbs are recombinant proteins capable to bind with SARS-CoV-2 preventing its entrance into cells. Several mAbs have shown reduction in viral load and/or progression of the disease such as casirivimab-imdevimab, bamlanivimab-etesevimab and sotrovimab. After the apparition of Omicron variant, it has been reported that sotrovimab retained its activity whereas the other two combinations exhibited loss of neutralizing activity. Several aspects as the target population, timing and doses, serological patient status and evolution of variants still require attention, monitorization and further studies for knowledge gaps.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Glicoproteína de la Espiga del Coronavirus
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio pronóstico
/
Revisiones
/
Revisión sistemática/Meta análisis
Tópicos:
Variantes
Límite:
Humanos
Idioma:
Inglés
Revista:
Rev Esp Quimioter
Asunto de la revista:
Terapia por drogas
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS